Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can pea fiber bread clean the blood of dialysis patients?

NCT ID NCT07544797

Disease control Sponsor: Martin-Luther-Universität Halle-Wittenberg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding pea fiber to the daily diet of people on dialysis can lower harmful waste products in their blood. 72 adults on dialysis will eat baked goods with or without pea fiber for 8 weeks. Researchers will measure changes in toxin levels and heart health markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pea fiber (prebiotic)
What this could lead to
If it works, this could offer a simple, food-based way to reduce harmful toxins and possibly lower heart disease risk in people on dialysis.
What could go wrong
This is a small, early-stage trial with only 72 participants. Previous studies on fiber have shown mixed results, so there is no guarantee it will work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * male and female patients 18-89 years of age * chronic hemodialysis treatment minimum 3 months for any kind of kidney disease * 2-3 hemodialysis sessions per week * expected to continue regular treatment for at least 3 months * written informed consent Exclusion Criteria: * Persons younger than 18 or older than 89 years * Clinically relevant infections at the time of the study or within 2 weeks prior to study inclusion * Use of immunosuppressive medications, with the exception of glucocorticoids ≤ 5 mg prednisolone equivalent * Liver cirrhosis, Child-Pugh stage C * Active malignancy, with or without specific oncological therapy * Blood transfusion within 4 weeks prior to inclusion, or severe anemia with a current indication for blood transfusion * Planned absence (e.g., vacation) for more than 1 week during the study period * Pregnancy * Intolerance to gluten, eggs, milk, yeast, nuts, or pea protein * Missing consent to participate in the study * Inability to understand the study content and procedures and to provide informed consent after appropriate explanation * Persons institutionalized by court or administrative order * Simultaneous participation in another interventional study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemodialysis Kidney failure, chronic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Martin-Luther-University Halle-Wittenberg

    Halle, Saxony-Anhalt, D06120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.